New data demonstrate that caplacizumab treatment accelerates normalization of platelet count in patients with acute episodes of acquired thrombotic thrombocytopenic purpura (TTP). Although not curative, this drug might reduce ischaemic organ damage and be potentially lifesaving for patients with TTP who do not respond to conventional therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies
Thrombosis Journal Open Access 04 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Peyvandi, F. et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 374, 511–522 (2016).
Rock, G. A. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N. Engl. J. Med. 325, 393–397 (1991).
Moake, J. L. et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 307, 1432–1435 (1982).
Furlan, M., Robles, R. & Lämmle, B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87, 4223–4234 (1996).
Levy, G. G. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413, 488–494 (2001).
Furlan, M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N. Engl. J. Med. 339, 1578–1584 (1998).
Callewaert, F. et al. Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 120, 3603–3610 (2012).
McClain, R. S. et al. Plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: 2011–2014. Transfusion 54, 3257–3259 (2014).
Jian, C. et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 119, 3836–3843 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.L. holds a patent on ADAMTS13 (US Patent Application. No. 14/247,116) and is Chairman of the Data Safety Monitoring Board of the BAX930 study of recombinant ADAMTS13 in hereditary TTP (NCT02216084). He has received congress travel support from Alexion, Baxalta and Siemens and speaker's fees from Siemens.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Lämmle, B. Caplacizumab accelerates resolution of acute acquired TTP. Nat Rev Nephrol 12, 259–260 (2016). https://doi.org/10.1038/nrneph.2016.47
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.47
This article is cited by
-
Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies
Thrombosis Journal (2016)
